<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02276482</url>
  </required_header>
  <id_info>
    <org_study_id>1986-012</org_study_id>
    <secondary_id>TR701-122</secondary_id>
    <secondary_id>2014-004023-40</secondary_id>
    <nct_id>NCT02276482</nct_id>
  </id_info>
  <brief_title>Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)</brief_title>
  <official_title>Phase 3 Study of IV to Oral 6-Day Tedizolid Phosphate Compared With 10-day Comparator in Subjects 12 to &lt; 18 Years With cSSTI.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cubist Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cubist Pharmaceuticals LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the safety of intravenous (IV) and/or oral 6-day 200
      mg tedizolid phosphate with 10-day comparator in participants 12 to &lt;18 years with cSSTI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, single-blind, multicenter, Phase 3 study of IV and/or oral tedizolid phosphate
      200 mg once per day for 6 days compared with IV and/or oral Comparator for 10 days for the
      treatment of cSSTI, also known as acute bacterial skin and skin structure infections, in
      participants 12 to &lt;18 years. cSSTI includes major cutaneous abscess, cellulitis/erysipelas,
      and wound infection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2015</start_date>
  <completion_date type="Anticipated">November 7, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 7, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events on Tedizolid Phosphate and Comparator Drugs</measure>
    <time_frame>Up to 39 days</time_frame>
    <description>The primary objective is to compare the safety of IV and/or oral 6-day 200 mg tedizolid phosphate with 10-day Comparator standard of care in participants 12 to &lt;18 years with cSSTI. Safety will be assessed through summaries of Treatment Emergent Adverse Events by treatment groups (tedizolid phosphate and other comparator drugs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Lesion Reduction Success</measure>
    <time_frame>25 days</time_frame>
    <description>To compare the programmatic early clinical response % in the tedizolid phosphate and comparator groups defined as a &gt;= 20% reduction from baseline lesion area in cm2 of erythema, edema or induration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Investigator's Assessment Indicating Clinical Success</measure>
    <time_frame>Treatment to Cure Visit: 18-25 days after first drug infusion</time_frame>
    <description>To compare the Investigator's assessment of clinical success in the tedizolid phosphate and Comparator groups at the Test of Cure (TOC; 18 to 25 days after the first infusion) Visit in the Intent to Treat (ITT) and Clinically Evaluable at TOC (CE-TOC) Analysis Sets.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Early Clinical Responses Measured by Lesion Reduction</measure>
    <time_frame>48-72 hours after first drug infusion</time_frame>
    <description>To compare the programmatic early clinical response in the tedizolid phosphate and Comparator groups at the 48-72 Hour Visit in the ITT Analysis Set</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Investigator's Assessment Indicating Early Clinical Success</measure>
    <time_frame>End of Therapy Visit: up to 13 days after first drug infusion</time_frame>
    <description>To compare the Investigator's assessment of clinical success in the tedizolid phosphate and Comparator groups at the End of Therapy (EOT) Visit (Day 11+2) in the ITT and CE-EOT Analysis Sets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of Tedizolid Phosphate</measure>
    <time_frame>Day 1, 48-72 hours, Day 7</time_frame>
    <description>Evaluate peak concentration of tedizolid phosphate after drug administration using validated assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) of Tedizolid Phosphate</measure>
    <time_frame>Day 1, 48-72 hours, Day 7</time_frame>
    <description>Evaluate systemic plasma concentration of tedizolid phosphate after drug administration using a validated assay.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Skin Diseases, Infectious</condition>
  <condition>Skin Diseases, Bacterial</condition>
  <arm_group>
    <arm_group_label>Tedizolid Phosphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV and/or oral 200 mg once per day for 6 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic comparator drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV and/or oral antibiotic comparator drug for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tedizolid Phophate 200 mg, IV and/or oral for 6 days</intervention_name>
    <arm_group_label>Tedizolid Phosphate</arm_group_label>
    <other_name>TR701-122</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotic comparator</intervention_name>
    <arm_group_label>Antibiotic comparator drug</arm_group_label>
    <other_name>Vancomycin, Linezolid, Clindamycin, Flucloxacillin, Cefazolin, Cephalexin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females 12 years to &lt;18 years

          -  Adequate venous access for IV administration of study drug for at least 24 hours (for
             participants receiving IV medication) and collection of protocol-specified blood
             samples

          -  Local symptoms must have started within 7 days before Study Day -1

          -  cSSTI meeting at least 1 of the clinical syndrome definitions.

          -  Suspected or documented Gram-positive infection from baseline Gram stain or culture.

          -  Parent/legally authorized representative (LAR) able to give informed consent and
             willing and able to comply with all required study procedures. Assent is also required
             of children who in the Investigator's judgment are capable of understanding the nature
             of the study

        Exclusion Criteria:

          -  Uncomplicated minor skin and skin structure infections such as pustules, folliculitis,
             furuncles, minor abscesses (small volume of suppuration not surrounded by
             cellulitis/erysipelas), impetiginous lesions, superficial or limited
             cellulitis/erysipelas, and minor wound associated foreign body reactions (eg, stitch
             abscesses)

          -  Known bacteremia, severe sepsis or septic shock

          -  Recent history of opportunistic infections where the underlying cause of these
             infections is still active (eg, leukemia, transplant, acquired immunodeficiency
             syndrome)

          -  Hypersensitivity to tedizolid phosphate or any component in the formulation

          -  Hypersensitivity to all of the comparator drugs; hypersensitivity to a comparator drug
             does not preclude participation if an alternative comparator can be used

          -  For participants with wound infections: history of hypersensitivity to ceftazidime,
             aztreonam, or any component of the aztreonam formulation, if aztreonam adjunctive
             therapy is required; history of hypersensitivity to metronidazole or any component of
             the formulation, if metronidazole adjunctive therapy is required

          -  Needs oral administration of methotrexate, topotecan, irinotecan or rosuvastatin,
             during administration of oral study drug.

          -  Uses monoamine oxidase inhibitors, tricyclic antidepressants, buspirone, selective
             serotonin reuptake inhibitors and serotonin 5 hydroxytryptamine receptor agonists
             (triptans) within 14 days prior to study drug administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0121)</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0119)</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0117)</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0101)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0116)</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0120)</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0100)</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0106)</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0110)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0118)</name>
      <address>
        <city>Pharr</city>
        <state>Texas</state>
        <zip>78577</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Bulgaria EOOD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florina Prundaru</last_name>
      <phone>40212333530</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme IDEA, Inc.</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betul Erdogan</last_name>
      <phone>2123361232</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Latvija SIA</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Moeschlin</last_name>
      <phone>460857813500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UAB &quot;Merck Sharp &amp; Dohme&quot;</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Moeschlin</last_name>
      <phone>460857813500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Polska Sp. Z o.o.</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas J. Johansson</last_name>
      <phone>48224784324</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD (Pty) LTD South Africa</name>
      <address>
        <city>Midrand</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoe Nell</last_name>
      <phone>27 116553307</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp and Dohme de Espana S.A.</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lourdes Lopez-Bravo</last_name>
      <phone>(0034) 913210654</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Ukraine LLC</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serhiy Mykhaylov</last_name>
      <phone>38 050 3107198</phone>
    </contact>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Georgia</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Panama</country>
    <country>Slovenia</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2014</study_first_submitted>
  <study_first_submitted_qc>October 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2014</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Soft Tissue Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Skin Diseases, Infectious</mesh_term>
    <mesh_term>Skin Diseases, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Torezolid</mesh_term>
    <mesh_term>Torezolid phosphate</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Oxazolidinones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

